Bridging a patient with acute liver failure to liver transplantation by the AMC-bioartificial liver.

Autori: van de Kerkhove M.P., Di Florio E., Scuderi V., Mancini A., Belli A., Bracco A., Scala D., Scala S., Zeuli L., Di Nicuolo G., Amoroso P., Calise F., Chamuleau R.A.

Data di Pubblicazione: 06-01-2003

Rivista: Cell Transplant. 2003;12(6):563-8.

Abstract:

Recently a phase I clinical trial has been started in Italy to bridge patients with acute liver failure (ALF) to orthotopic liver transplantation (OLT) by the AMC-bioartificial liver (AMC-BAL). The AMC-BAL is charged with 10 x 10(9) viable primary porcine hepatocytes isolated from a specified pathogen-free (SPF) pig. Here we report a patient with ALF due to acute HBV infection. This patient was treated for 35 h by two AMC-BAL treatments and was bridged to OLT. There was improvement of biochemical and clinical parameters during the treatment. No severe adverse events were observed during treatment and follow-up of 15 months after hospital discharge. Possible porcine endogenous retrovirus (PERV) activity could not be detected in the patient’s blood or blood cells up to 12 months after treatment.

L’articolo non è free. Per il FULL TEXT contattaci via email: biotecnologie@aocardarelli.it / documentazione@aocardarelli.it